The global blood screening market, valued at USD 3.40 billion in 2024, is projected to expand at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. This anticipated growth is largely due to a global increase in blood donations, which heightens the need for rigorous screening processes to detect transfusion-transmissible infections and ensure patient safety. Advances in technology, especially in automation and molecular platforms, are making blood screening faster, more accurate, and more efficient. Additionally, the growing prevalence of infectious diseases, coupled with government initiatives to promote safe blood practices, has driven public awareness of the importance of blood screening. These factors collectively contribute to the market’s expansion.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Regional Insights:

North America Blood Screening Market Trends

In 2024, North America dominated the global blood screening market, accounting for the largest revenue share at 38.4%. The region’s healthcare infrastructure is highly advanced, with a strong focus on patient safety, supported by cutting-edge blood screening technology. Growing awareness around the importance of early disease detection has prompted healthcare providers in North America to prioritize routine blood screening. The collaboration between public health organizations and private sectors in the U.S. and Canada further enhances access to quality blood screening services, sustaining growth in this region.

U.S.

The U.S. market led the North American blood screening sector in 2024, driven by a high volume of blood donations and stringent regulations for blood safety. The country’s focus on secure blood transfusions creates demand for comprehensive blood screening methods. Innovations in testing technology contribute to higher accuracy and faster processing times, while favorable reimbursement policies encourage healthcare providers to adopt the latest screening technologies, ultimately improving public health outcomes.

Asia Pacific Blood Screening Market Trends

The Asia Pacific blood screening market is expected to experience the fastest growth, with a projected CAGR of 13.7% over the forecast period. Factors such as increasing healthcare awareness, economic growth, and significant investments in healthcare infrastructure are enhancing access to blood screening services in the region. The rising rates of infectious diseases have intensified the need for effective blood screening methods, and government initiatives promoting preventive healthcare are further driving demand. This makes Asia Pacific a key market for potential innovation and expansion in blood screening technology.

Japan

Japan’s blood screening market is set to grow substantially, supported by the country’s advanced technology sector and focus on preventive healthcare. Increased public awareness about the importance of health check-ups and blood safety, combined with a growing aging population, has driven demand for diagnostic services to manage chronic conditions. Government support for blood donation and improved screening technologies upholds Japan’s high standards in blood safety and contributes to market growth.

Europe Blood Screening Market Trends

Europe’s blood screening market is projected to expand significantly, largely due to stringent regulatory standards and a strong focus on patient safety. Many countries in Europe have established robust blood testing frameworks that emphasize quality control and risk management. The rise in infectious diseases has heightened the demand for advanced screening technologies, and public-private partnerships have enhanced access to these innovations across the continent, promoting overall public health.

Germany

In Germany, the blood screening market benefits from a strong emphasis on innovation and quality assurance within its healthcare system. Rigorous testing protocols ensure accurate and reliable results, while increased awareness of blood-borne diseases drives demand for effective screening methods. The German government’s initiatives to promote routine health check-ups, coupled with the country’s active research environment, support advancements in diagnostic technology and improve the effectiveness of blood screening practices.

Browse through Grand View Research's Category Clinical Diagnostics Industry Research Reports.

Key Companies & Market Share Insights:

Leading players in the blood screening market, including Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd., Grifols, S.A., and Abbott Laboratories, employ various strategies to maintain competitiveness and expand their market reach. These companies pursue strategic collaborations to drive innovation, engage in mergers and acquisitions to enhance capabilities, and frequently launch new products to address evolving healthcare needs.

Abbott Laboratories

Abbott Laboratories is a global leader in medical technology, offering specialized equipment that leverages advanced blood screening components to ensure high durability and lightweight properties. Beyond blood screening, Abbott operates in other medical sectors, such as laboratory diagnostics, cardiovascular devices, diabetes care, and nutrition. This diverse portfolio positions Abbott as a prominent player in healthcare, addressing a broad spectrum of medical needs.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a key player in diagnostics, developing instruments that integrate blood screening materials for enhanced performance and reliability. Apart from blood screening, Bio-Rad is also involved in areas like quality control, gene expression analysis, and protein purification. This wide range of expertise strengthens Bio-Rad’s position as a leading company in both research and clinical diagnostics, allowing it to serve a variety of healthcare needs across global markets.

Key Blood Screening Companies:

  • Abbott
  • Danaher Corporation (Beckman Coulter)
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Hoffman-La Roche Ltd.
  • Grifols, S.A.
  • Ortho-Clinical Diagnostics, Inc.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
  • SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.